Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis.
Paolo GisondiC VirgaS PiasericoA MeneguzzoGiulia OdoriciAndrea ContiG GirolomoniPublished in: The British journal of dermatology (2020)